Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · May 06, 2015

FOLFIRI Plus Bevacizumab as Second-Line Therapy in Patients With Metastatic Colorectal Cancer

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
FOLFIRI Plus Bevacizumab as Second-Line Therapy in Patients With Metastatic Colorectal Cancer After First-Line Bevacizumab Plus Oxaliplatin-Based Therapy: The Randomized Phase III EAGLE Study
Ann. Oncol 2015 Apr 23;[EPub Ahead of Print], S Iwamoto, T Takahashi, H Tamagawa, M Nakamura, Y Munemoto, T Kato, T Hata, T Denda, Y Morita, M Inukai, K Kunieda, N Nagata, K Kurachi, K Ina, M Ooshiro, T Shimoyama, H Baba, K Oba, J Sakamoto, H Mishima

Further Reading